Gregory M. Cote, MD, PhD (he/him/his)

Assistant Professor
Mass General Cancer Center

Dr. Cote is a medical oncologist and clinical investigator at the Mass General Cancer Center in the Center for Sarcoma and Connective Tissue Oncology and the Henri and Belinda Termeer Center for Targeted Therapies (Phase I). He specializes in developmental therapeutics for patients with sarcoma and other connective tissue malignancies.

Poster(s):

• (P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA

• (P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS

• (P 338) PREOPERATIVE RADIATION THERAPY IS NOT ASSOCIATED WITH ADVERSE POSTOPERATIVE OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA